

What Is Claimed Is:

1. A combination comprising a therapeutically-
5 effective amount of an angiotensin converting enzyme
inhibitor and an epoxy-steroidal aldosterone receptor
antagonist, said epoxy-steroidal aldosterone receptor
antagonist being present in an amount which is
therapeutically effective to antagonize aldosterone but
10 which amount is not sufficient for said aldosterone
receptor antagonist to induce a substantially adverse
side effect.

2. The combination of Claim 1 wherein said
15 aldosterone receptor antagonist is an epoxy-steroidal-
type compound characterized in having a 9 α -,11 α -
substituted epoxy moiety.

3. The combination of Claim 2 wherein said
20 epoxy-steroidal-type compound is eplerenone.

4. The combination of Claim 1 wherein
angiotensin converting enzyme inhibitor is selected from
the group consisting of alacepril, benazepril, captopril,
25 cilazapril, delapril, enalapril, enalaprilat, fosinopril,
fosinoprilat, imidapril, lisinopril, perindopril,
quinapril, ramipril, saralasin acetate, temocapril,
trandolapril, ceranapril, moexipril, quinaprilat,
spirapril, Bioproject BP1.137, Chiesi CHF 1514, Fisons
30 FPL-66564, idrapril, Marion Merrell Dow MDL-100240,
perindoprilat, and Servier S-5590.

5. The combination of Claim 4 wherein said
angiotensin converting enzyme inhibitor is selected from
35 the group consisting of alacepril, benazepril, captopril,
cilazapril, delapril, enalapril, enalaprilat, fosinopril,
fosinoprilat, imidapril, lisinopril, perindopril,
quinapril, ramipril, saralasin acetate, temocapril,

trandolapril, ceranapril, moexipril, quinaprilat, and spirapril.

6. The combination of Claim 1 further
5 characterized by said angiotensin converting enzyme
inhibitor and said aldosterone receptor antagonist being
present in said combination in a weight ratio range from
about 0.5-to-one to about twenty-to-one of said
angiotensin converting enzyme inhibitor to said
10 aldosterone receptor antagonist.

7. The combination of Claim 6 wherein said
weight ratio range is from about one-to-one to about
fifteen-to-one.
15

8. The combination of Claim 7 wherein said
weight ratio range is from about one-to-one to about
five-to-one.

20 9. A combination therapy for treating
cardiovascular disorders in a subject afflicted with or
susceptible to multiple cardiovascular disorders, wherein
said combination therapy comprises administering a
therapeutically-effective amount of a two-component
25 combination consisting essentially of an angiotensin
converting enzyme inhibitor as a first component and an
epoxy-steroidal aldosterone receptor antagonist as a
second component in an amount therapeutically effective
to antagonize aldosterone but insufficient to induce an
30 adverse side effect.

10. The combination therapy of Claim 9 wherein
said subject is afflicted with or susceptible to heart
failure and said subject further requires avoidance of
35 the incidence of hyperkalemia.

11. The combination therapy of Claim 10 wherein said subject is further susceptible to congestive heart failure.

5 12. The combination therapy of Claim 10 wherein said subject is further susceptible to hypertension.

10 13. The combination therapy of Claim 10 further characterized by administering said angiotensin converting enzyme inhibitor and said epoxy-steroidal aldosterone receptor antagonist.

15 14. The combination therapy of Claim 10 further characterized by administering said angiotensin converting enzyme inhibitor and said epoxy-steroidal aldosterone receptor antagonist in a substantially simultaneous manner.

20 15. The combination therapy of Claim 9 wherein said epoxy-steroidal aldosterone receptor antagonist is a compound characterized in having a 9 α -11 α -substituted epoxy moiety.

25 16. The combination therapy of Claim 15 wherein said epoxy-steroidal compound is eplerenone.

30 17. The combination therapy of Claim 9 wherein said angiotensin converting enzyme inhibitor is selected from the group consisting of alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, saralasin acetate, temocapril, trandolapril, ceranapril, moexipril, 35 quinaprilat, spirapril, Bioproject BP1.137, Chiesi CHF 1514, Fisons FPL-66564, idrapril, Marion Merrell Dow MDL-100240, perindoprilat, and Servier S-5590.

18. The combination therapy of Claim 17 wherein said angiotensin converting enzyme inhibitor is selected from the group consisting of alacepril, benazepril, captopril, cilazapril, delapril, enalapril, 5 enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, saralasin acetate, temocapril, trandolapril, ceranapril, moexipril, quinaprilat, and spirapril.

10 19. The combination therapy of Claim 9 further characterized by said angiotensin converting enzyme inhibitor and said epoxy-steroidal aldosterone receptor antagonist being used in said co-therapy in a weight ratio range from about 0.5-to-one to about twenty-to-one 15 of said angiotensin converting enzyme inhibitor to said aldosterone receptor antagonist.

20 20. The combination therapy of Claim 19 wherein said weight ratio range is from about one-to-one to about fifteen-to-one.

25 21. The combination therapy of Claim 20 wherein said weight ratio range is from about one-to-one to about five-to-one.

22. The combination therapy of Claim 9 wherein said angiotensin converting enzyme inhibitor is captopril, in a dose range from about 40 mg to about 80 mg per dose, or is enalapril in a dose range from about 5 30 mg to about 25 mg per dose.

23. The combination therapy of Claim 22 wherein said epoxy-steroidal aldosterone receptor antagonist is eplerenone in a dose range from about 25 mg 35 to about 100 mg per dose.